Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial

OBJECTIVE

To evaluate the efficacy and safety of long-term budesonide therapy for the maintenance of clinical remission in patients with collagenous colitis.

DESIGN

Randomised, placebo-controlled study with a 24-week, blinded follow-up period without any treatment.

SETTING

Three gastroenterology clinics in Denmark.

PATIENTS

Forty-two patients with histologically confirmed collagenous colitis and diarrhoea (more than three stools/day).

INTERVENTIONS

Patients in clinical remission after 6 weeks' open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks' double-blind maintenance therapy with budesonide 6 mg/day or placebo. Thereafter, patients entered the 24-week, blinded follow-up period.

MAIN OUTCOME MEASURE

The proportion of patients in clinical remission (three or fewer stools/day) at the end of maintenance therapy.

FINDINGS

A total of 34 patients in remission at week 6 were randomly assigned to budesonide 6 mg/day (n = 17) or placebo (n = 17). After 24 weeks' maintenance treatment, the proportions of patients in clinical remission were 76.5% (13 of 17) with budesonide and 12% (2 of 17) with placebo (p<0.001). At 48 weeks (the end of the follow-up period, without any treatment) these values were 23.5% (4 of 17) and 12% (2 of 17), respectively (p = 0.6). The median times to relapse after stopping active treatment (6 plus 24 weeks in the budesonide group; 6 weeks in the placebo group) were 39 and 38 days, respectively. Long-term treatment with budesonide was well tolerated.

CONCLUSIONS

Long-term maintenance therapy with oral budesonide is efficacious and well tolerated for preventing relapse in patients with collagenous colitis. The risk of relapse after 24 weeks' maintenance treatment is similar to that observed after 6 weeks' induction therapy.

Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis

BACKGROUND

Collagenous colitis is characterised by diarrhoea, lymphocytic inflammation, and a thickened subepithelial collagen layer in the colorectal mucosa. No standard treatment of the disease is established.

AIMS

To investigate the clinical and histological effect of oral budesonide (Entocort, AstraZeneca) in the treatment of collagenous colitis.

PATIENTS

Twenty patients with collagenous colitis (collagen layer >10 micro m) and diarrhoea (>4 stools/day and/or stool weight >200 g/day).

METHODS

A randomised, double blind, placebo controlled trial of budesonide treatment. Patients were randomised to placebo or budesonide for eight weeks. Stool frequency and stool weight were registered before and after treatment. Sigmoidoscopy was performed before and after treatment, and biopsies at fixed locations were obtained for morphometric analysis.

RESULTS

Ten patients were randomised to budesonide and 10 to placebo. All 10 patients receiving budesonide had a clinical response compared with two in the placebo group (p<0.001). In the budesonide group, stool weight was reduced from 574 g/day to 200 g/day and stool frequency was reduced from 6.2/day to 1.9/day (p<0.01). The histological inflammation grade in the sigmoid mucosa and the thickness of the collagen layer were significantly reduced. A correlation between the grade of inflammation as well as collagen layer thickness and stool weight was found. No side effects were reported. Eight of 10 patients had relapse of symptoms within eight weeks after stopping treatment.

CONCLUSIONS

Budesonide is a highly effective and well tolerated treatment of collagenous colitis. There is a high risk of relapse after stopping eight weeks of treatment.

Collagenous colitis: a long-term follow-up study

OBJECTIVE

Collagenous colitis was first described in 1976. It is a rare disorder and the long-term course and prognosis of the disease are unknown. The aim of this study was to evaluate the course of the disease more than 5 years after the diagnosis.

DESIGN

A retrospective follow-up of patients with collagenous colitis diagnosed during the period 1979-1990.

METHODS

All examinations performed at the time of diagnosis were reviewed and the clinical courses of the patients were determined by evaluation of the medical records. At a follow-up visit in 1996 complete histories were obtained and conventional laboratory tests were performed.

RESULTS

Two men and 22 women aged 20-82 years with collagenous colitis were identified. At the time of diagnosis, extensive investigation did not reveal other gastrointestinal diseases. At the time of follow-up, six patients had died from diseases unrelated to collagenous colitis, 10 patients suffered from chronic or intermittent diarrhoea, and four patients had been without gastrointestinal symptoms for the last 2-10 years. None of the patients developed colorectal cancer or chronic inflammatory bowel disease. Four patients were lost to follow-up.

CONCLUSION

Collagenous colitis is a benign disease, most often with a chronic course. No association with other gastrointestinal diseases was found.

[Transmission of hepatitis B from an adopted child to an adult]

A case of acute hepatitis B infection in a 43 year-old male is presented. Seven months before admission the family had adopted a two year-old boy from India, and the child was later found to be seropositive for HBsAg. The patient had no other risk factors of hepatitis B infection and transmission of hepatitis B virus from the adopted child is suspected. It is recommended that children who are adopted from countries with high hepatitis B virus prevalence should be examined for HBsAg, and adoptive family members be vaccinated if the child is found to be HBsAg seropositive.